Risk and prognostic significance of tuberculosis in patients from The TREAT Asia HIV Observational Database by Zhou, Jialun et al.
BioMed  Central
Page 1 of 9
(page number not for citation purposes)
BMC Infectious Diseases
Open Access Research article
Risk and prognostic significance of tuberculosis in patients from The 
TREAT Asia HIV Observational Database
Jialun Zhou*1, Julian Elliott1, Patrick CK Li2,  P o hL i a nL i m 3, 
Sasisopin Kiertiburanakul4, Nagalingeswaran Kumarasamy5, 
Tuti Parwati Merati6, Sanjay Pujari7, Yi-Ming A Chen8, Praphan Phanuphak9, 
Saphonn Vonthanak10, Thira Sirisanthana11, Somnuek Sungkanuparph4, 
Christopher KC Lee12, Adeeba Kamarulzaman13, Shinichi Oka14, 
Fujie Zhang15, Goa Tau16 and Rossana Ditangco17
Address: 1National Centre in HIV Epidemiology and Clinical Research The University of New South Wales, Sydney, Australia, 2Department of 
Medicine, Queen Elizabeth Hospital, Hong Kong, PR China, 3Tan Tock Seng Hospital, Singapore, 4Faculty of Medicine Ramathibodi Hospital, 
Mahidol University, Bangkok, Thailand, 5YRG Centre for AIDS Research and Education, Chennai, India, 6School of Medicine Udayana University 
& Sanglah Hospital, Denpasar, Bali, Indonesia, 7Institute of Infectious Diseases, Pune, India, 8Taipei Veterans General Hospital and AIDS 
Prevention and Research Centre, National Yang-Ming University, Taipei, Taiwan, 9HIV-NAT/Thai Red Cross AIDS Research Centre, Bangkok, 
Thailand, 10National Center for HIV/AIDS, Dermatology & STDs, Phnom Penh, Cambodia, 11Research Institute for Health Sciences, Chiang Mai, 
Thailand, 12Hospital Sungai Buloh, Kuala Lumpur, Malaysia, 13University of Malaya, Kuala Lumpur, Malaysia, 14International Medical Centre of 
Japan, Tokyo, Japan, 15Beijing Ditan Hospital, Beijing, PR China, 16Port Moresby General Hospital, Port Moresby, Papua New Guinea and 
17Research Institute for Tropical Medicine, Manila, the Philippines
Email: Jialun Zhou* - jzhou@nchecr.unsw.edu.au; Julian Elliott - elliott@burnet.edu.au; Patrick CK Li - lickp@ha.org.hk; 
Poh Lian Lim - Poh_Lian_Lim@ttsh.com.sg; Sasisopin Kiertiburanakul - rasal@mahidol.ac.th; 
Nagalingeswaran Kumarasamy - kumarasamy@yrgcare.org; Tuti Parwati Merati - tutiparwati@yahoo.com; 
Sanjay Pujari - sanjaypujari@gmail.com; Yi-Ming A Chen - arthur@ym.edu.tw; Praphan Phanuphak - ppraphan@chula.ac.th; 
Saphonn Vonthanak - research03@nchads.org; Thira Sirisanthana - thira@rihes.org; Somnuek Sungkanuparph - rasuy@mahidol.ac.th; 
Christopher KC Lee - chrislee@hkl.gov.my; Adeeba Kamarulzaman - ADEEBA@ummc.edu.my; Shinichi Oka - oka@imcj.acc.go.jp; 
Fujie Zhang - treatment@chinaids.org.cn; Goa Tau - gtau@daltron.com.pg; Rossana Ditangco - raditangco@yahoo.com
* Corresponding author    
Abstract
Background: To assess the risk and the prognostic significance of tuberculosis (TB) diagnosis in
patients from The TREAT Asia HIV Observational Database, a multi-centre prospective cohort of
HIV-infected patients receiving HIV care in the Asia-Pacific region.
Methods: The risk of TB diagnosis after recruitment was assessed in patients with prospective
follow-up. TB diagnosis was fitted as a time-dependent variable in assessing overall survival.
Results: At baseline, 22% of patients were diagnosed with TB. TB incidence was 1.98 per 100
person-years during follow up, with predictors including younger age, lower recent CD4 count,
duration of antiretroviral treatment, and living in high TB burden countries. Among 3279 patients
during 6968 person-years, 142 died (2.04 per 100 person-years). Compared to patients with CDC
category A or B illness only, mortality was marginally higher in patients with single Non-TB AIDS
defining illness (ADI), or TB only (adjusted HR 1.35, p = 0.173) and highest in patients with multiple
non-TB AIDS or both TB and other ADI (adjusted HR 2.21, p < 0.001).
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Conclusion: The risk of TB diagnosis was associated with increasing immunodeficiency and partly
reduced by antiretroviral treatment. The prognosis of developing TB appeared to be similar to that
following a diagnosis of other non-TB ADI.
Background
The use of highly active antiretroviral therapy (HAART)
has led to dramatic reductions in morbidity and mortality
in HIV patients [1,2]. However, tuberculosis (TB) remains
a common opportunistic infections and a major cause of
death among patients with HIV, especially in sub-Saharan
African and Asian countries [3-5], where there is a high
background prevalence of TB [5-7].
The risk of TB in HIV-infected patients and the impact of
TB diagnosis on disease progression in HIV infected
patients have been well described in Africa [3,8-10]. The
Asia-Pacific region has a large burden of both tuberculosis
[7], with nearly 5 million prevalent cases and over 3 mil-
lion new cases in 2006, and HIV, with an estimated 5 mil-
lion people living with HIV and 380,000 new infections
occurring in 2007 [11]. It is estimated that 2.5 million
people are living with both infections in the region [5].
Despite the importance of these inter-related epidemics in
the region, few studies have evaluated the risk of TB or its
prognostic impact in patients with HIV [12-14].
Using data from The TREAT Asia HIV Observational Data-
base (TAHOD), a multicentre prospective cohort study
involving 17 clinical sites in the Asia-Pacific region, this
paper aims to assess:
1) The risk of, and factors associated with, TB diagnosis
among TAHOD patients with prospective follow up;
2) The prognostic significance of TB diagnosis on overall
survival.
Methods
TAHOD is a collaborative observational cohort study
involving 17 sites in the Asia-Pacific region (See appen-
dix). Detailed methods are published elsewhere [15].
Briefly, each site recruited 200 patients, including both
patients on or not initiating HAART. Recruitment was
based on a consecutive series of patients regularly attend-
ing a given site from a particular start-up time. Ethical
approval for the study was obtained from the University
of New South Wales Ethics Committee and respective
local ethics committee.
The following data were collected: patient demographics
and baseline data, CD4 and CD8 count, HIV RNA level,
prior and new AIDS defining illness (ADI), date and cause
of death, prior and current prescribed HAART, and reason
for treatment change. Data are collected according to a
common protocol. Upon recruitment, all available data
prior to entry to TAHOD (considered as retrospective
data) are extracted from patient case notes. Prospective
data are updated six-monthly at each clinic and trans-
ferred to data management centre for aggregation and
analyses. TAHOD sites are encouraged to contact patients
who were not seen in the clinics in the previous 12
months.
TB diagnosis is defined as definitive when there is isola-
tion (or culture) of Mycobacterium tuberculosis, Mycobacte-
rium bovis or  Mycobacterium africanum from a clinical
specimen. TB is presumptively diagnosed when there is
demonstration of acid-fast bacilli in a clinical specimen,
or in a histopathological lesion when a culture is not
available, in a person with signs or symptoms compatible
with tuberculosis; or evidence of resolution of disease
where treatment with two or more anti-tuberculosis med-
ications have been prescribed and follow-up has been
instigated.
Information on availability and regimen of TB treatment
and prophylaxis were collected by surveying TAHOD
sites. Anti-TB treatment is available to all HIV patients
who are diagnosed with active TB in all participating
TAHOD sites, with isoniazid, rifampicin, pyrazinamide
and ethambutol given as intensive phase for at least 2
months, followed by isoniazid with either rifampicin or
streptomycin or ethambutol as continuation phase for 4
to 10 months. TB prophylaxis is not available for patients
at 13 of the 17 sites. For the 4 sites that provide prophy-
laxis, isoniazid is given for 6 to 12 months, to around less
than 5% to 40% of the HIV patients, and is based on CD4
count (<200 cells/μL), a positive tuberculin skin test or
recent close contact with another patient with active
tuberculosis.
TAHOD sites were grouped into two categories, high and
low/intermediate TB burden, according to WHO TB
reports [16]. The high TB burden group included sites
from China, Cambodia, India, Indonesia, the Philippines
and Thailand. The low/intermediate burden group
included sites from Hong Kong, Taiwan, Malaysia, Singa-
pore and Japan.
Patients who had at least one prospective follow-up visit
after entry to TAHOD were included. Baseline characteris-
tics were compared between patients with and without aBMC Infectious Diseases 2009, 9:46 http://www.biomedcentral.com/1471-2334/9/46
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prior TB diagnosis (a TB diagnosis within 7 days after
entry to TAHOD). Factors associated with baseline TB
were assessed using univariate and multivariate logistic
regression models.
The risk of TB among patients with prospective follow up
was assessed using the person-time method. Follow-up
was censored at date of TB diagnosis, or death, or the date
of the most recent visit. Predictors of TB diagnosis were
assessed using Cox proportional hazards models. ADI
(including TB) diagnosed within 7 days after entry to
TAHOD were considered as pre-existing events (prior
diagnoses). The first diagnoses of TB during prospective
follow up were included, which also included the pro-
spectively diagnosed TB among patients with prior TB.
Overall survival after entry to TAHOD was also assessed
using the person-time method. Follow-up was from entry
to TAHOD until date of death or censored at date of the
most recent visit. Death was reported using standardised
cause of death form and independently reviewed by a cli-
nician in the data coordinating centre. TB was separated
from the list of other ADIs in this analysis since the aim
was to compare the impact on disease progression of TB
diagnosis with other ADIs. Patient's disease stage was
updated when CDC category B illness, TB, or any other
ADI was diagnosed during follow up. Baseline TB and
incident TB were included as time-dependent variables in
assessing overall survival. Disease stage was categorised as
"CDC category A disease", "CDC category B disease", "TB
only", "TB and CDC category B disease", "single non-TB
ADI", "multiple non-TB ADIs" and "TB and other ADIs".
Cox proportional hazards models were used to assess risk
factors associated with TB diagnosis and overall survival.
In analyses of TB incidence and overall survival, antiretro-
viral treatment and CD4 counts were fitted as time
dependent variables. The observations of each patient
were updated at each time when there was a treatment
change or a new CD4 count. Antiretroviral therapy was
included in the model following the intention to treat
principle, and was categorised according to the duration
on treatment. We included the time-updated HIV viral
load in the final survival model, the coefficient of disease
stage in predicting survival, which is our primary interest,
remains almost identical. Due to concerns about the miss-
ing data and collinearity, we decided not to include HIV
viral load in the model.
Analysis was performed using the statistical package
STATA (StataCorp LP 2007, STATA 10 for Windows, Col-
lege Station, Texas 77845 USA). Predictors were assessed
using multiple logistic or Cox proportional hazards mod-
els with a forward stepwise approach. The final multivari-
ate model included covariates that remained significant at
the 0.05 level (2-sided). Non-significant variables were
also presented and adjusted for final multivariate models.
Results
By June 2007, a total of 3516 patients had been recruited
to TAHOD, including 3279 (93%) patients with at least
one prospective follow up. The overall follow up rate in
TAHOD is 85%. At entry to TAHOD, 759 (of 3516, 22%
of all patients) had prior diagnosis of TB, among whom
717 (of 3279, 22%) had at least one prospective follow
up. Up to 90% of the patients had at least one CD4 test
during follow up and the median number of CD4 tests in
each patient was 4 (IQR 2 to 7). However, just 58% of the
patients had at least one HIV viral load test and the
median number of RNA test was 4 (IQR 2 to 5). 830
patients were not on HAART at baseline and 412 of them
started treatment during follow up. Most patients were
initiated with combination treatment with at least two
nucleoside reverse transcriptase inhibitors and one non-
nucleoside reverse transcriptase inhibitors (73% of 2449
patients on treatment at baseline).
Baseline demographic characteristics are shown in Table
1. Patients with prior TB were less likely to be female,
more likely of age between 31 to 40 years (compared to
age less than 30 years), less likely to report HIV infection
through homosexual contact or injecting drug use (com-
pare to heterosexual contact), more likely to have lower
CD4 counts and have no HIV viral load tests, and more
likely to receive antiretroviral treatment and come from
countries with high TB burden.
Among the 3279 patients with at least one prospective fol-
low up, 135 patients developed TB, giving a TB incidence
of 1.98 per 100 person-years (95% confidence interval
[CI] 1.67–2.34). CD4 count at time of TB diagnosis was
available in 83 patients, with a median 159 cells/μL (IQR
50 – 261). Most of the TB diagnoses were definitive (92 of
135, 68%) or presumptive (30 of 135, 22%); there were
13 cases of possible TB (10%). However, no more infor-
mation was collected in TAHOD regarding the availability
of routine culture from the sites. Sites of TB infection were
distributed as follows: pulmonary (60 of 135, 44%),
extra-pulmonary (19 of 135, 14%), both pulmonary and
extra-pulmonary TB (4 of 135, 3%) and unknown (52 of
135, 39%). The median TB incidence from the sites in low
burden countries is 0.50 per 100 person years (IQR 0.46
to 0.57), while in high burden countries, 3.02 (IQR 0.98
to 4.85).
Factors associated with the rate of prospective TB diagno-
sis are presented in Table 2. In multivariate models, fac-
tors remaining included younger age, lower recent CD4
count, duration of antiretroviral treatment, and living in
high TB burden countries. Patients aged more than 40BMC Infectious Diseases 2009, 9:46 http://www.biomedcentral.com/1471-2334/9/46
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years had significantly lower rate of TB diagnosis than that
of patients aged 30 or younger (adjusted HR 0,47, p =
0.003). A higher CD4 count was associated with a signifi-
cantly lower rate of TB diagnosis. Compared to patients
who were not receiving antiretroviral treatment, there was
a significant increase in the rate of TB diagnosis within 90
days after initiating treatment (adjusted HR 4.01, p = <
0.001). The rate of TB diagnosis decreased continuously
with the increase of duration of antiretroviral treatment.
The rate of TB diagnosis was significantly lower among
patients living in countries with low/intermediate TB bur-
den than those in countries with high TB burden
(adjusted HR 0.21, p = < 0.001). Although prior TB diag-
nosis was associated with higher rate of prospective TB (p
= 0.038), it lost statistical significance after adjustments.
A total of 142 deaths were recorded among 3279 patients
during 6968 years of prospective follow up, a mortality
rate of 2.04 per 100 person-years (95% CI 1.73–2.40). 69
deaths were reported to be directly related to HIV-associ-
ated illnesses (16 due to TB), 49 deaths due to other rea-
sons, and cause of death was unknown for 24.
Factors associated with overall mortality are presented in
Table 3. In multivariate analysis, mortality was higher in
patients aged more than 40 years, with lower CD4 counts
and who were not receiving antiretrovirals. Mortality also
appeared to worsen when CDC category B illness, TB, or
any other ADI was diagnosed during follow up. Com-
pared to patients with CDC category A disease only, mor-
tality was greatest in patients with multiple ADIs other
than TB (adjusted HR 2.27, p = 0.007) and patients with
both TB and at least one other ADI (adjusted HR 2.12, p =
0.004).
Table 1: Baseline characteristics associated with prior TB diagnosis
Univariate Multivariate
Characteristics No. patients No.(%) with prior TB OR p-value OR (95%CI) p-value
Total 3279 717 (22%)
Sex
Male 2307 582 (25%)
Female 972 135 (14%) 0.48 <0.001 0.38 (0.30, 0.47) <0.001
Age (years)
< = 30 783 141 (18%)
31~40 1481 366 (25%) 1.49 <0.001 1.39 (1.10, 1.76) 0.006
41+ 1015 210 (21%) 1.19 0.155 1.16 (0.89, 1.51) 0.261
Reported mode of infection
Heterosexual contact 2288 584 (26%)
Homosexual contact 614 66 (11%) 0.35 <0.001 0.47 (0.34, 0.63) <0.001
Injecting drug use 132 34 (26%) 1.01 0.952 0.73 (0.47, 1.12) 0.154
Blood product 120 11 (9%) 0.29 <0.001 0.29 (0.15, 0.56) <0.001
Other/unknown 125 22 (18%) 0.62 0.049 0.60 (0.37, 0.98) 0.042
CD4 count at entry to TAHOD (cells/μL)
< = 50 241 84 (35%)
51–100 209 78 (37%) 1.11 0.587 1.06 (0.74, 1.59) 0.780
101–200 524 142 (27%) 0.69 0.029 0.71 (0.50, 1.00) 0.054
201–300 578 121 (21%) 0.49 <0.001 0.58 (0.41, 0.83) 0.003
301+ 1487 217 (15%) 0.32 <0.001 0.42 (0.30, 0.58) <0.001
Not tested 240 75 (31%) 0.85 0.401 0.91 (0.61, 1.38) 0.665
HIV viral load at entry to TAHOD (copies/mL)
< = 399 1133 188 (17%)
400~10,000 188 24 (13%) 0.74 0.187 0.93 (0.58, 1.50) 0.774
10,001+ 405 54 (13%) 0.77 0.123 0.92 (0.64, 1.32) 0.652
No. not tested 1553 451 (29%) 2.06 <0.001 1.36 (1.05, 1.76) 0.018
Antiretroviral treatment at entry to TAHOD
No treatment 830 117 (14%)
On treatment 2449 600 (25%) 1.98 <0.001 1.99 (1.56, 2.56) <0.001
Country of TB burden
High 1990 547 (27%)
Low/intermediate 1289 170 (13%) 0.40 <0.001 0.55 (0.42, 0.70) <0.001
OR: odds ratio. CI: confidence intervals.BMC Infectious Diseases 2009, 9:46 http://www.biomedcentral.com/1471-2334/9/46
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After fitting the Cox proportional hazards models, further
testing of coefficients found that the mortalities were sim-
ilar between patients with CDC category A and with B ill-
ness only (p = 0.433); among patients with TB only, with
TB and CDC category B illness or with single non-TB ADI
(p = 0.430); and between patients with multiple non-TB
ADI and with TB and at least one other ADI (p = 0.410).
Table 4 summarises the adjusted hazard ratios of these
disease stages, initially separated, and then aggregated.
Compared to patients with CDC category A or B illness
only, mortality was marginally higher in patients with sin-
gle Non-TB ADI, or TB only (adjusted HR 1.35, p = 0.173)
and highest in patients with multiple non-TB AIDS or
both TB and other ADI (adjusted HR 2.21, p < 0.001).
Discussion
This study found a baseline prevalence of previous TB
diagnosis of over 20% and a rate of prospective TB diag-
nosis during prospective follow up of 1.79 per 100 per-
son-years. Prognosis following diagnosis of TB appeared
to be no worse than following other ADI diagnoses.
We previously found [15] a higher prevalence of ADIs at
study entry in TAHOD compared with cohorts in Western
countries [17,18]. Much of the disparity in the prevalence
Table 2: Risk factors associated with TB diagnosis
Univariate Multivariate
No. of patients Follow up (years) No. of events Rate HR p HR (95% CI) p-value
Total 3279 6815 135 1.98
Sex
Male 2307 4883 100 2.05
Female 972 1932 35 1.81 0.88 0.510 0.77 (0.52, 1.14) 0.198
Age at entry of TAHOD (years)
< = 30 1103 2203 56 2.54
31~40 1401 2944 60 2.04 0.81 0.249 0.80 (0.56, 1.16) 0.237
41+ 775 1668 19 1.14 0.45 0.003 0.47 (0.28, 0.79) 0.005
Reported mode of infection
Heterosexual contact 2288 4896 102 2.08
Homosexual contact 614 1243 16 1.29 0.62 0.074 1.29 (0.74, 2.23) 0.367
Injecting drug use 132 260 11 4.23 2.03 0.026 1.03 (0.54, 1.97) 0.917
Blood products 120 197 0 0.00 --- --- --- ---
Other/unknown 125 219 6 2.74 1.29 0.544 0.94 (0.41, 2.15) 0.877
CDC classification for HIV infection *
Category A 1747 3497 48 1.37
Category B 622 1158 39 3.37 2.42 <0.001 1.33 (0.86, 2.05) 0.203
Category C 1020 2160 48 2.22 1.62 0.017 1.37 (0.89, 2.10) 0.150
CD4 count (cells/μL) *
< = 50 313 251 27 10.74
51–100 312 222 15 6.74 0.64 0.162 0.69 (0.36, 1.29) 0.243
101–200 928 842 30 3.56 0.34 <0.001 0.41 (0.24, 0.69) 0.001
201–300 1224 1250 23 1.84 0.17 <0.001 0.21 (0.12, 0.37) <0.001
301+ 2225 4197 30 0.71 0.07 <0.001 0.08 (0.05, 0.14) <0.001
Not tested 68 53 10 18.98 1.83 0.106 1.02 (0.48, 2.15) 0.969
Prior TB diagnosis
No 2562 5254 94 1.79
Yes 717 1561 41 2.63 1.47 0.038 1.08 (0.74, 1.59) 0.684
Antiretroviral treatment *
No treatment 830 985 40 4.06
Treated, 0~90 days 453 83 14 16.91 4.01 <0.001 2.52 (1.31, 4.84) 0.006
Treated, 91–180 days 674 147 9 6.11 1.45 0.328 0.96 (0.45, 2.04) 0.909
Treated, 181–360 days 1017 414 5 1.21 0.30 0.013 0.24 (0.09, 0.62) 0.003
Treated 361+ days 2452 5186 57 1.29 0.30 <0.001 0.40 (0.26, 0.61) <0.001
Country of TB burden
High 1990 3644 115 3.16
Low/intermediate 1289 3171 20 0.63 0.21 <0.001 0.28 (0.17, 0.45) <0.001
Rate: per 100 person years. HR: hazard ratio. CI: confidence interval.
* Time dependent variable, patients can contribute person time to more than one category thus the sum of the categories may be more than the 
total number of patients.BMC Infectious Diseases 2009, 9:46 http://www.biomedcentral.com/1471-2334/9/46
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of pre-existing ADI between TAHOD and western cohorts
can be attributed to tuberculosis. [18-20]. In this analysis,
patients from countries with high TB burden had a base-
line prevalence of prior TB diagnosis of 27% and an inci-
dence during follow up of 3.02 per 100 patient years,
consistent with high TB burden countries in Asia [21] and
Africa [9,22]. Although the prevalence of prior TB diagno-
sis in countries with low or intermediate TB burden was
approximately half of that in countries with high TB bur-
den countries in Asia, this risk was still higher than that
seen in western cohorts [23,24].
During follow up the rate of prospective TB diagnosis was
associated with a lower recent CD4 count, but not disease
stages according to CDC classification. This discordance
could partly be explained by the non directional nature of
disease staging. Patients with category C disease treated
with HAART have a reduced risk of TB, which reflected in
the increase of CD4 count, but the disease stage does not
change. Nevertheless, these data illustrate the ubiquity of
TB risk across all stages of HIV infection.
Prior TB has been reported to increase the risk of subse-
quent TB [25]. In this study, however, prior TB lost statis-
Table 3: Risk factors associated with overall survival
Univariate Multivariate
No. of patients Follow up (years) No. of events Rate HR p HR (95% CI) p-value
Total 3279 6968 142 2.04
Sex
Male 2307 4992 105 2.10
Female 972 1976 37 1.87 0.89 0.527 1.07 (0.73, 1.57) 0.732
Age at entry of TAHOD (years)
< = 30 1103 2270 40 1.76
31~40 1401 3016 50 1.66 0.95 0.812 0.86 (0.57, 1.32) 0.497
41+ 775 1682 52 3.09 1.78 0.006 1.79 (1.18, 2.71) 0.006
Reported mode of infection
Heterosexual contact 2288 5013 97 1.94
Homosexual contact 614 1261 12 0.95 0.47 0.014 0.68 (0.21, 1.25) 0.368
Injecting drug use 132 276 14 5.08 2.54 0.001 1.40 (0.27, 2.53) 0.772
Blood products 120 196 7 3.58 1.77 0.144 1.57 (0.26, 3.44) 0.721
Other/unknown 125 222 12 5.40 2.65 0.001 1.63 (0.12, 3.01) 0.883
CD4 count (cells/μL) *
< = 50 316 268 51 19.02
51–100 325 246 16 6.49 0.35 <0.001 0.37 (0.21, 0.66) 0.001
101–200 939 875 20 2.29 0.12 <0.001 0.14 (0.08, 0.24) <0.001
201–300 1238 1276 19 1.49 0.08 <0.001 0.10 (0.06, 0.17) <0.001
301+ 2242 4244 22 0.52 0.03 <0.001 0.04 (0.02, 0.07) <0.001
Not tested 68 59 14 23.68 1.18 0.592 0.86 (0.46, 1.58) 0.622
Country of TB burden
High 1990 3775 95 2.52
Low/intermediate 1289 3193 47 1.47 0.62 0.007 0.86 (0.60, 1.26) 0.435
Antiretroviral treatment *
No treatment 830 1006 44 4.37
Treated, 0~90 days 475 88 8 9.14 1.89 0.103 1.08 (0.50, 2.35) 0.846
Treated, 91–180 days 703 154 5 3.24 0.67 0.405 0.39 (0.15, 0.99) 0.049
Treated, 181–360 days 1048 428 21 4.91 1.06 0.838 0.73 (0.42, 1.27) 0.265
Treated 361+ days 2478 5292 64 1.21 0.31 <0.001 0.32 (0.21, 0.51) <0.001
Disease stage *
CDC Category A 1444 2900 37 1.28
CDC Category B 442 824 12 1.46 1.15 0.679 0.95 (0.49, 1.84) 0.886
TB only 328 634 13 2.05 1.65 0.122 1.53 (0.80, 2.91) 0.197
TB + CDC Category B 202 382 8 2.09 1.70 0.175 0.99 (0.45, 2.16) 0.976
Single non-TB ADI 523 1035 22 2.13 1.69 0.051 1.40 (0.80, 2.42) 0.237
Multiple non-TB ADIs 212 461 19 4.12 3.34 <0.001 2.27 (1.25, 4.10) 0.007
TB and other ADI(s) 336 732 31 4.23 3.57 <0.001 2.12 (1.27, 3.55) 0.004
Rate: per 100 person years. HR: hazard ratio. CI: confidence interval. ADI: AIDS defining illness.
* Time dependent variable, patients can contribute person time to more than one category thus the sum of the categories may be more than the 
total number of patients.BMC Infectious Diseases 2009, 9:46 http://www.biomedcentral.com/1471-2334/9/46
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tical significance after adjustment, which is similar to
findings from Lawn et al [10]. According to TAHOD sites,
anti-TB treatment is available to all HIV patients who are
diagnosed with active TB, which might provide at least
time-limited reduction in the risk of TB in HIV patients
[26].
Following HAART initiation, the rate of TB diagnosis was
highest within 90 days after treatment initiation. Previ-
ously we have reported the increased rate of AIDS diagno-
sis shortly after HAART initiation in TAHOD [27]. It is
probably due to immune reconstitution syndrome
[28,29]; however, it is difficult in this observational set-
ting to verify these cases with limited evidence collected.
It could also be the fact that patients were generally more
immune suppressed when HAART was initiated.
The rate of TB diagnosis decreased continuously with the
increase of duration of antiretroviral treatment, but still
above the estimated population incidence for the South-
East Asian and Western Pacific regions [7]. This is consist-
ent with the incomplete nature of TB-specific immune res-
toration [30] and emphasises the limitations of HAART in
reversing the impact of the HIV epidemic on TB control
[31]. HAART is usually commenced towards the end of a
long period of increased TB risk [32] and although associ-
ated with a reduction in TB incidence, [3,21,23,24,33] this
is off-set to some degree by increased survival and conse-
quent longer period at risk. It is possible that further
reductions in TB incidence during ART could be achieved
through treatment of latent TB infection. Since only a
small proportion of patients in TAHOD received isoniazid
preventive therapy, its impact on the incidence of pro-
spective TB diagnosis or interaction of effect with ART
could not be assessed in this study.
In this cohort of patients with access to HAART when clin-
ically indicated according to local treatment guidelines,
there was a borderline significant increase in adjusted
overall mortality, when comparing patients developing
TB and no other ADI to those with no HIV-related illness.
The adjusted hazard for death for patients developing TB
only was similar to those developing other single AIDS
defining illnesses, and when these groups were combined
their risk of mortality was marginally different to patients
with Category A or B disease. Similarly, in patients devel-
oping more than one ADI, TB seemed to carry a similar
additional hazard of death as other ADIs. The data suggest
that in a diverse population of people living with HIV in
Asia with ready access to ART, the prognostic implication
of active tuberculosis is more similar to other ADIs than
CDC Category B disease. In individual patients, the prog-
nostic utility of TB is limited by the wide spectrum of
immunodeficiency present at the time of clinical presen-
tation. Nevertheless, these data are consistent with consid-
eration of TB as an indicator of a level of
immunodeficiency for which initiation or change of ART
is indicated in the absence of CD4 count.
A number of limitations should be considered when inter-
preting the above findings. Firstly, TAHOD is a newly
established cohort with relatively small number of end-
points and prospective TB diagnosis. Thus statistical anal-
yses have limited power to differentiate the prognostic
significance of TB diagnosis, CDC stage B diagnosis and
other ADIs. This also limited our ability to investigate the
risk of TB by duration of HAART, HIV RNA level, treat-
ment of latent TB or the prognostic significance of pulmo-
nary versus extra-pulmonary disease. Secondly, TAHOD
patients cannot be seen as entirely representative of HIV
patients in the Asia-Pacific region as participating sites are
generally urban referral centres. Thirdly, although the fol-
low-up rate in TAHOD is satisfactory, ADI and other
important events might be under-reported due to a
patient not regularly visiting the clinics or if a patient dies.
There may also be delay in reporting of AIDS diagnosis
Table 4: Adjusted hazard ratios of disease stages on overall survival
Disease stage Adjusted HR (95% CI) p-value Combined Disease stage Adjusted HR (95% CI) p-value
CDC Category A CDC Category A or B
CDC Category B 0.95 (0.49, 1.84) 0.886
TB only 1.53 (0.80, 2.91) 0.197 TB only, or TB + CDC Category B, or Single 
non-TB ADI
1.35 (0.88, 2.07) 0.173
TB + CDC Category B 0.99 (0.45, 2.16) 0.976
Single non-TB ADI 1.40 (0.80, 2.42) 0.237
Multiple non-TB ADIs 2.27 (1.25, 4.10) 0.007 Multiple non-TB ADIs, or TB and other 
ADI(s)
2.21 (1.43, 3.42) <0.001
TB and other ADI(s) 2.12 (1.27, 3.55) 0.004
HR: hazard ratio. CI: confidence interval. ADI: AIDS defining illness.
Adjusted for age, CD4 count and antiretroviral treatments.BMC Infectious Diseases 2009, 9:46 http://www.biomedcentral.com/1471-2334/9/46
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and death. And finally, CD4 counts and antiretroviral
treatment are correlated; in particular, treatment leads to
increases in CD4 count, has an impact on disease progres-
sion (CDC category) and so improves survival. The objec-
tive of this analysis was to estimate the role of TB on rate
of death, and clearly treatment, CD4 count and CDC cat-
egory are all confounders. The ARV treatment effects esti-
mated from our models on the incidence of TB diagnosis
and subsequent survival could indeed be biased as they
are also adjusted for current and subsequent CD4 counts
and CDC category.
However, the comparison of the effect of TB and other
CDC category on survival should remain robust, and we
believe should be adjusted for these factors. Specific mod-
elling, such as marginal structural modelling [34] or G-
estimation [35], which adjusts for the relationship
between time-varying confounding factors and treat-
ments, would need to be applied if the interest is to look
at the effect of antiretroviral treatment on the develop-
ment of TB and/or survival
Conclusion
In conclusion, the diversity in rates of TB seen in TAHOD
patients reflects the diversity in background population
TB incidence seen across Asia-Pacific region. Risk of TB
disease was also associated with increasing immunodefi-
ciency and was only partly reduced by antiretroviral treat-
ment. Following the diagnosis of TB, the prognosis
appeared to be similar to that following a diagnosis of
other AIDS defining illnesses. Competing interestsThe
authors declare there are no competing interests.
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